The use of topical Povidone Iodine (PVP-I) oropharyngeal and intranasal application during the current coronavirus pandemic as a potential measure to reduce viral transmission

INTERVENTION: Intervention1: Povidone Iodine: 2% Povidone Iodine gargle diluted to 1% (w/v) is used as oropharyngeal gargle and intranasal application given 4 times to 48 laboratory tested COVID‐19 patients and followed up for 12 weeks Control Intervention1: normal saline: 48 patients laboratory tested COVID‐19 positive selected and tested on 7th and 21st day for comparison and followed for 12 weeks to check for any relapse CONDITION: Health Condition 1: B972‐ Coronavirus as the cause of diseases classified elsewhere PRIMARY OUTCOME: comparing the reduction in the progression, transmission of disease in 48 participants taking oropharyngeal gargles and intranasal application of PVP‐I in comparison to the control group not doing the same for which patients in both the group will be tested for viral load on 7 th and 21 st day. Spread of the disease can be checked by confirming if the nasal / oropharyngeryngel swabs turn negative and no contacts turn covid‐19 positiveTimepoint: The study group will be tested for covid‐19 to check for negativity on & 7th and 21st day following intervention SECONDARY OUTCOME: Early recovery from infection and no relapse of infection. patients will be tested on 7th day and 21st day to confirm if they have turned negative . early negative will be an indicative of early recovery. Also even if any of the patients have co morbid factors and they do not turn serious that will suggest that disease progression is controlledTimepoint: 12 to 14 weeks INCLUSION CRITERIA: All patients laboratory tested COVID‐19 positive above 18 years of age +/‐ two days of admission